PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development
09 févr. 2024 08h10 HE
|
PharmAla Biotech
PharmAla signs all-cash agreement to consult for Red Light Holland
PharmAla releases Profitable Q1 Interim Financial Statement and Business Update
31 janv. 2024 10h58 HE
|
PharmAla Biotech
PharmAla releases Profitable Q1 Interim Financial Statement, and will host investor webinar to discuss prominent changes to the business & FDA timelines
PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada
25 janv. 2024 12h09 HE
|
PharmAla Biotech
PharmAla granted a Health Canada Controlled Drugs and Substances Dealer's License
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
24 janv. 2024 09h35 HE
|
PharmAla Biotech
PharmAla recieved a new OTCQB ticker, MDXXF.
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
08 janv. 2024 08h55 HE
|
PharmAla Biotech
PharmAla announces that its novel P1 molecule has been accepted by USPTO to its accelerated "Patent Prosecution Highway"
PharmAla Files Audited Financials for Year Ending August 31, 2023
29 déc. 2023 16h00 HE
|
PharmAla Biotech
PharmAla releases audited year-end financials for the period ended August 31st.
PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules
15 nov. 2023 08h55 HE
|
PharmAla Biotech
PharmAla Biotech contracted with Filament Health to manufacture a second batch of MDMA capsules; manufacturing is complete and shipped to clients.
World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment
09 nov. 2023 08h55 HE
|
PharmAla Biotech
PharmAla partners with Heroic Hearts Canada and the University of Calgary to launch the world's first observational rial into MDMA's real-world efficacy
PharmAla Partners with Clariti Strategic Advisors™
08 nov. 2023 08h55 HE
|
PharmAla Biotech
PharmAla signs long-term partnership with Clariti Strategic Partners as its investment banking and advisory firm
PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa
07 nov. 2023 08h55 HE
|
PharmAla Biotech
PharmAla completes the historic first shipment of MDMA and Psilocybin to its Australian Joint Venture, Cortexa, for use in commercial patient treatments